JP2023531390A5 - - Google Patents

Info

Publication number
JP2023531390A5
JP2023531390A5 JP2022576009A JP2022576009A JP2023531390A5 JP 2023531390 A5 JP2023531390 A5 JP 2023531390A5 JP 2022576009 A JP2022576009 A JP 2022576009A JP 2022576009 A JP2022576009 A JP 2022576009A JP 2023531390 A5 JP2023531390 A5 JP 2023531390A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
acceptable salt
cycloalkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022576009A
Other languages
English (en)
Japanese (ja)
Other versions
JP7797421B2 (ja
JP2023531390A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/099654 external-priority patent/WO2021249534A1/zh
Publication of JP2023531390A publication Critical patent/JP2023531390A/ja
Publication of JP2023531390A5 publication Critical patent/JP2023531390A5/ja
Priority to JP2025277389A priority Critical patent/JP2026053536A/ja
Application granted granted Critical
Publication of JP7797421B2 publication Critical patent/JP7797421B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022576009A 2020-06-12 2021-06-11 フタラジノン化合物、並びにその調製方法及びその医薬用途 Active JP7797421B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025277389A JP2026053536A (ja) 2020-06-12 2025-12-23 フタラジノン化合物、並びにその調製方法及びその医薬用途

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN202010536221 2020-06-12
CN202010536221.6 2020-06-12
CN202011147078.8 2020-10-23
CN202011147078 2020-10-23
CN202011261665 2020-11-12
CN202011261665.X 2020-11-12
CN202110485680 2021-04-30
CN202110485680.0 2021-04-30
CN202110614030.1 2021-06-02
CN202110614030 2021-06-02
PCT/CN2021/099654 WO2021249534A1 (zh) 2020-06-12 2021-06-11 酞嗪酮类化合物及其制备方法和医药用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025277389A Division JP2026053536A (ja) 2020-06-12 2025-12-23 フタラジノン化合物、並びにその調製方法及びその医薬用途

Publications (3)

Publication Number Publication Date
JP2023531390A JP2023531390A (ja) 2023-07-24
JP2023531390A5 true JP2023531390A5 (cg-RX-API-DMAC7.html) 2024-06-19
JP7797421B2 JP7797421B2 (ja) 2026-01-13

Family

ID=78846889

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022576009A Active JP7797421B2 (ja) 2020-06-12 2021-06-11 フタラジノン化合物、並びにその調製方法及びその医薬用途
JP2025277389A Pending JP2026053536A (ja) 2020-06-12 2025-12-23 フタラジノン化合物、並びにその調製方法及びその医薬用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025277389A Pending JP2026053536A (ja) 2020-06-12 2025-12-23 フタラジノン化合物、並びにその調製方法及びその医薬用途

Country Status (18)

Country Link
US (3) US20230131252A1 (cg-RX-API-DMAC7.html)
EP (1) EP4166550A4 (cg-RX-API-DMAC7.html)
JP (2) JP7797421B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230024328A (cg-RX-API-DMAC7.html)
CN (2) CN113801098B (cg-RX-API-DMAC7.html)
AU (1) AU2021286738A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025057A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186981A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003472A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022017802A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230007A (cg-RX-API-DMAC7.html)
IL (1) IL298962A (cg-RX-API-DMAC7.html)
MX (1) MX2022015562A (cg-RX-API-DMAC7.html)
PE (1) PE20230610A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023550018A1 (cg-RX-API-DMAC7.html)
SA (1) SA522441725B1 (cg-RX-API-DMAC7.html)
TW (1) TWI781651B (cg-RX-API-DMAC7.html)
WO (1) WO2021249534A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
AU2020414151A1 (en) 2019-12-23 2022-08-25 Jiangxi Jemincare Group Co., Ltd Protein degradation agent compound preparation method and application
CA3174353A1 (en) * 2020-04-08 2021-10-14 Dominic Reynolds Compounds and methods for modulating splicing
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
KR20230024328A (ko) 2020-06-12 2023-02-20 상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 프탈라지논 화합물, 이의 제조 방법 및 이의 의학적 용도
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
KR102474999B1 (ko) * 2021-05-26 2022-12-07 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
JP2024519628A (ja) * 2021-05-26 2024-05-21 イノキュア セラピューティクス インコーポレイテッド ピペリジンジオン誘導体
WO2023016518A1 (zh) 2021-08-11 2023-02-16 四川海思科制药有限公司 一种杂环衍生物及其组合物和药学上的应用
US20260159520A1 (en) * 2022-09-08 2026-06-11 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2024054952A1 (en) * 2022-09-08 2024-03-14 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
JP2025538554A (ja) * 2022-11-22 2025-11-28 イノキュア セラピューティクス,インコーポレイテッド Brdタンパク質を分解するための分解剤およびそれを含有する薬学的組成物
EP4624472A1 (en) * 2022-11-22 2025-10-01 Innocure Therapeutics, Inc. Degrader including novel c-met protein ligand and pharmaceutical composition including same
EP4624466A1 (en) * 2022-11-22 2025-10-01 Innocure Therapeutics, Inc. Degrader for decomposing cmet protein, and pharmaceutical composition comprising same
CN116655591B (zh) * 2023-06-05 2024-11-08 中国人民解放军军事科学院军事医学研究院 3,4-二氢酞嗪-1(2h)-酮类衍生物及制备方法和用途
EP4763845A1 (en) 2023-08-17 2026-06-24 Haisco Pharmaceutical Group Co., Ltd. Cyano aromatic ring derivative and pharmaceutical use thereof
EP4780815A1 (en) 2023-09-20 2026-07-29 Aurigene Oncology Limited Heterocyclic compounds as cbp selective degraders
WO2025085738A1 (en) 2023-10-18 2025-04-24 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2025108406A1 (zh) * 2023-11-22 2025-05-30 广东东阳光药业股份有限公司 一种靶向降解雄激素受体的双功能嵌合体的杂环化合物及其用途
AU2024392985A1 (en) 2023-12-08 2026-06-04 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
WO2025189056A1 (en) 2024-03-08 2025-09-12 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease
TW202600539A (zh) 2024-03-13 2026-01-01 美商建南德克公司 Ar降解劑之多形體
WO2025193851A1 (en) 2024-03-13 2025-09-18 Genentech, Inc. Process for making enantiomers of ar-degraders
WO2025226797A1 (en) 2024-04-24 2025-10-30 Genentech, Inc. Kred catalyzed ketoreduction of a cyclobutanone carbamic ester
US12169941B1 (en) 2024-06-13 2024-12-17 Rapsodo Pte. Ltd. System and method for determining a position an object crosses a target plane

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245804B1 (en) * 1997-05-30 2001-06-12 Schering Aktiengesellschaft Nonsteroidal gestagens
DE19723722A1 (de) * 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
EP4649963A3 (en) 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
CA2988414C (en) 2015-06-04 2023-09-26 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
SI3526202T1 (sl) * 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
US10842878B2 (en) 2016-11-22 2020-11-24 Dana-Farber Cancer Institute, Inc. Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
AU2017363257B2 (en) 2016-11-22 2021-08-19 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
IL319363A (en) 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
CN110194762B (zh) * 2018-02-27 2021-09-10 中国科学院上海药物研究所 酞嗪酮类衍生物、其制备方法和用途
CN112390852B (zh) 2019-08-14 2022-10-18 上海济煜医药科技有限公司 作为蛋白降解剂的化合物及其制备方法和应用
CN112457367B (zh) 2019-09-06 2022-08-23 上海济煜医药科技有限公司 作为蛋白降解剂的连环类化合物及其制备方法和应用
CN118085015A (zh) 2019-09-06 2024-05-28 江西济民可信集团有限公司 作为蛋白降解剂的并环类化合物及其制备方法和用途
CN112574278B (zh) 2019-09-29 2024-08-23 江西济民可信集团有限公司 作为蛋白降解剂杂环类化合物及其制备方法和医药应用
AU2020414151A1 (en) 2019-12-23 2022-08-25 Jiangxi Jemincare Group Co., Ltd Protein degradation agent compound preparation method and application
CN113582974B (zh) 2020-04-30 2022-05-17 江西济民可信集团有限公司 一类作为蛋白降解剂的化合物及其制备方法和医药用途
KR20230024328A (ko) 2020-06-12 2023-02-20 상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 프탈라지논 화합물, 이의 제조 방법 및 이의 의학적 용도

Similar Documents

Publication Publication Date Title
JP2023508097A5 (cg-RX-API-DMAC7.html)
FI4129989T3 (fi) Dipeptidyylipeptidaasi 1:n estäjänä toimiva nitriilijohdannainen ja sen käyttö
RU2009115963A (ru) Производные оксадиазола, обладающие противовоспалительными и иммунодепрессантными свойствами
JP2019104748A5 (cg-RX-API-DMAC7.html)
JP2019513778A5 (cg-RX-API-DMAC7.html)
JP2011519854A5 (cg-RX-API-DMAC7.html)
RU2007123235A (ru) Противоопухолевые соединения
JP2022119852A5 (cg-RX-API-DMAC7.html)
RU2009123525A (ru) ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2
RU2006116628A (ru) Новые производные имидазола и их применение в качестве фармацевтических агентов
JP2005526836A5 (cg-RX-API-DMAC7.html)
JP2017510660A5 (cg-RX-API-DMAC7.html)
RU2013120556A (ru) 1,2-гидрокси-2-оксо-хинолин-3-карбоксанилиды в качестве активаторов ahr
JP2022533939A5 (cg-RX-API-DMAC7.html)
JP2023553428A5 (cg-RX-API-DMAC7.html)
JP2010520276A5 (cg-RX-API-DMAC7.html)
JP2024526499A5 (cg-RX-API-DMAC7.html)
NO20063330L (no) Amidderivater med en syklopropylaminokarbonylsubstituent som er nyttige som cytokininhibitorer
JP2018527324A5 (cg-RX-API-DMAC7.html)
JP2008517897A5 (cg-RX-API-DMAC7.html)
RU2007147597A (ru) Производные эрголина и их применение в качестве лигандов хемокинного рецептора
JP2006523626A5 (cg-RX-API-DMAC7.html)
JP2013537193A5 (cg-RX-API-DMAC7.html)
JP2024539922A5 (cg-RX-API-DMAC7.html)
JP2007518798A5 (cg-RX-API-DMAC7.html)